Phibro Animal Health (NASDAQ:PAHC) Announces Earnings Results, Beats Estimates By $0.04 EPS

Key Points

• Q1 beat: Phibro reported $0.76 EPS vs. $0.72 expected and revenue of $383.5M vs. $367.0M, and updated FY2026 guidance to $2.98–$3.10 EPS.
• Shares jumped to $58.50 on the news; the company has a market cap of $2.37B, a P/E of 26.0 and a PEG of 0.86.
• Phibro declared a quarterly dividend of $0.12 (annualized $0.48, yield ~0.8%), while insiders — including the CEO — have been selling stock recently (281,600 shares sold in the last 90 days).

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) announced its earnings results on Wednesday. The company reported $0.76 EPS for the quarter, topping analysts' consensus estimates of $0.72 by $0.04, FiscalAI reports. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The company had revenue of $383.54 million for the quarter, compared to analysts' expectations of $367.02 million. Phibro Animal Health updated its FY 2026 guidance to 2.980-3.100 EPS.

Phibro Animal Health Price Performance

PAHC stock traded up $2.26 during trading on Wednesday, reaching $58.50. The company's stock had a trading volume of 300,750 shares, compared to its average volume of 260,342. Phibro Animal Health has a 1 year low of $19.00 and a 1 year high of $60.08. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14. The company has a market capitalization of $2.37 billion, a P/E ratio of 26.00, a price-to-earnings-growth ratio of 0.86 and a beta of 0.61. The company's fifty day moving average is $54.07 and its 200-day moving average is $46.48.

Phibro Animal Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 24th. Shareholders of record on Wednesday, June 3rd will be paid a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Wednesday, June 3rd. Phibro Animal Health's dividend payout ratio is presently 21.33%.

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, CEO Jack Bendheim sold 7,040 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $52.76, for a total value of $371,430.40. Following the completion of the sale, the chief executive officer owned 74,760 shares in the company, valued at approximately $3,944,337.60. This represents a 8.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 281,600 shares of company stock valued at $14,334,853. Corporate insiders own 50.13% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. iSAM Funds UK Ltd purchased a new position in shares of Phibro Animal Health during the third quarter valued at about $61,000. EverSource Wealth Advisors LLC grew its position in shares of Phibro Animal Health by 7,671.4% during the second quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company's stock valued at $69,000 after purchasing an additional 2,685 shares in the last quarter. C M Bidwell & Associates Ltd. grew its position in shares of Phibro Animal Health by 1,756.5% during the fourth quarter. C M Bidwell & Associates Ltd. now owns 2,135 shares of the company's stock valued at $80,000 after purchasing an additional 2,020 shares in the last quarter. Advisory Services Network LLC purchased a new position in shares of Phibro Animal Health during the third quarter valued at about $96,000. Finally, Tower Research Capital LLC TRC grew its position in shares of Phibro Animal Health by 768.2% during the second quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company's stock valued at $118,000 after purchasing an additional 4,079 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently commented on PAHC. Morgan Stanley set a $49.00 target price on Phibro Animal Health in a report on Friday, February 6th. Citigroup started coverage on Phibro Animal Health in a research note on Wednesday, April 15th. They issued a "neutral" rating and a $62.00 price target for the company. Finally, Zacks Research upgraded Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, March 11th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $42.40.

About Phibro Animal Health

Phibro Animal Health Corporation NASDAQ: PAHC is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.